Eph receptors, the largest subfamily of receptor tyrosine kinases, and their ephrin ligands play important roles in nervous system development. Recently, they have been implicated in tumorigenesis of different cancers. In this study, we showed that the expression of ephrinA5 was dramatically downregulated in primary gliomas compared with normal tissues. Forced expression of ephrinA5 reduced tumorigenicity of human glioma U373 cells. Epidermal growth factor receptor (EGFR), which frequently acts as an oncoprotein in glioma, was greatly decreased in ephrinA5-transfected glioma cells, and the two molecules exhibited a mutually exclusive expression pattern in primary glioma samples. We found that ephrinA5 enhanced c-Cbl binding to EGFR, thus promoted ubiquitylation and degradation of the receptor. Either ephrinA5-Fc or EphA2-Fc treatment simulating bidirectional signaling of Eph/ephrin system resulted in EGFR decrease. This study discovered that ephrinA5 acted as a tumor suppressor in glioma, and its negative regulation of EGFR contributed to the suppressive effects. In addition to identifying a novel mechanism underlying tumor suppressor activity of ephrinA5, we also showed cross-talk between different receptor tyrosine kinase families in glioma. These findings may improve therapeutic strategies for glioma.
Introduction
Eph/ephrin family members are expressed in adult human tissues and in the developing nervous system (Hafner et al., 2004) . The Eph receptors are unique among the receptor tyrosine kinases (RTKs) in that their endogenous ligands, the ephrins, are bound to the surface of neighboring cells. Ephrins are divided into two major classes, differing by their modes of attachment to plasma membrane (Gale et al., 1996) . Class A ephrins are tethered to the plasma membrane by virtue of a glycosylphosphatidylinositol anchor, whereas class B ephrins are transmembrane proteins. All of the ephrins interact with specific Eph receptors, although promiscuity exists as some ephrins bind to more than one Eph receptor. This receptor-ligand system is involved in a variety of biological events (Poliakov et al., 2004; Huberman et al., 2005; Kuijper et al., 2007) . Although a majority of investigators have studied the role of Eph/ ephrin in development, emerging evidence suggests strong involvement in tumorigenesis, including metastasis, invasion, and angiogenesis (Surawska et al., 2004; BrantleySieders et al., 2006; Liu et al., 2007) .
Gliomas are the most common primary brain tumors with limited therapeutic options, high recurrence rate and mortality. The epidermal growth factor receptor (EGFR) and its ligands figure prominently in glioma pathogenesis, and the malignant nature of glioma is partially due to the aberrance of EGFR, including gene amplification, mutation, abnormal overexpression, and improper activation of the receptor and its downstream signaling (Nicholas et al., 2006) . Considering the importance of RTKs in brain tumors, investigation into RTK networks provides a better understanding of the biology of glioma. However, studies concerning the cross-talk between Eph/ephrin and ErbB families are rare. In this study, we showed that ephrinA5, a member belonging to ephrinA subclass, could negatively regulate EGFR, which contributed to its suppressive effect in glioma. A mutually exclusive expression pattern between EGFR and ephrinA5 was disclosed in both stable cell lines and clinical tissue samples. We further revealed that ephrinA5 acted as a negative regulator of EGFR through promoting c-Cbl-mediated degradation. Importantly, both ephrinA5-Fc and EphA2-Fc fusion protein treatment led to decreased level of EGFR. Therefore, the bidirectional signaling, which is characteristic of the Eph/ephrin system, is involved in ephrinA5-induced EGFR reduction. Thus, we have identified a novel mechanism of EGFR regulation in glioma. Our findings may provide the assets for developing improved therapeutic strategies.
Results
EphrinA5 was expressed at a low level in primary glioblastomas We examined the expression pattern of ephrinA5 in both quick-frozen brain samples (23 glioblastoma multiforme and 5 normal) and primary cells (derived from 23 glioblastoma multiforme and 5 normal) by realtime PCR. Four out of five normal tissues exhibited significantly higher ephrinA5 expression level compared with tumor tissues (Figure 1a) . The similar expression pattern of ephrinA5 was also observed in primary cells (Figure 1b ). We performed immunohistochemistry in both normal and tumor tissues. As shown in Figure 1c , ephrinA5 protein was easily detected in normal tissues, exhibiting pronounced membrane staining. In contrast, it was almost undetectable in tumor tissues. Downregulation of ephrinA5 at both mRNA and protein level in glioma suggested its role as a tumor suppressor.
Forced expression of ephrinA5 in glioma cells reduced their clonogenic growth in soft agar and tumorigenicity in nude mice To examine the potential suppressive effects of ephrinA5 in glioma, we established stable cell lines using human glioma U373 cells. Two identified clones exhibiting different levels of ephrinA5 were selected for further studies (U373/ephrinA5L and U373/ephrinA5H, Figure 2c ). EphrinA5 showed little effect on cell proliferation in MTT (3-(4,5-dimethylthiazol-2-Yl)-2,5-diphenyltetrazolium bromide) assay (data not shown). In contrast, U373/ephrinA5 cells developed significantly fewer and smaller colonies in soft agar compared with U373/v cells (Figure 2a) , indicating its inhibitory effect on anchorage-independent clonogenic growth.
We further examined whether ephrinA5 would affect the tumorigenicity of glioma cells in vivo. U373/v and U373/ephrinA5 cells were subcutaneously injected into 8-week-old nude mice, and the resulting tumors were measured at the end of 4 weeks. U373/ephrinA5 cells barely developed any observable tumors, whereas the tumors derived from U373/v cells were easily visible and measurable. A significant difference in tumor volume between the two groups was revealed by statistical analysis (Po0.05, Figure 2b ). These results proved the suppressive effect of ephrinA5 in glioma.
EphrinA5 downregulated either the basal or the phosphorylation level of EGFR and impaired EGFR signaling in glioma cells To investigate the underlying mechanism for reduced tumorigenicity of glioma cells by ephrinA5, we examined the expression of several important molecules involved in tumorigenesis and development of glioma. We found that the expression level of EGFR was significantly decreased in U373/ephrinA5 cells ( Figure 2c ). The significant decrease of EGFR was also observed in both U343 and U373 cells infected with a virus vector overexpressing ephrinA5 (Figure 2d ). On the basis of this data, we investigated the expression pattern of ephrinA5 and EGFR in glioma tissue samples. As shown in Figure 3a , the expression of Expression of both basal and phosphorylation level of epidermal growth factor receptor (EGFR) was examined in U343 and U373 cells, which was infected with either control (U343 con, U373 con) or virus vector overexpressing ephrinA5 (U343/ ephrinA5, U373/ephrinA5). The same examination was also conducted in U373/v and U373/ephrinA5H cells. Figure 3 Mutually exclusive pattern of epidermal growth factor receptor (EGFR) and ephrinA5 in glioma tissue samples, and reduced response to epidermal growth factor (EGF) stimulation in U373/ephrinA5 cells. (a) Expressions of EGFR and ephrinA5 in 18 glioma samples examined by western blot. Blot densities were quantified by densitometry using Scion Image beta 4.03. Statistical analysis was carried out with Pearson correlation test. (b) Impaired response to EGF stimulation in U373/ephrinA5 cells. Cells were plated in a 24-well plate at a density of 80% confluence. After being starved overnight, cells were stimulated with 20 ng/ml EGF. Protein samples were collected at the indicated time points, and the level of ERK1/2 and phospho-ERK1/2 (p-ERK1/2) (pY202/pY204) was examined by western blot.
EphrinA5 suppresses tumorigenesis in glioma J-J Li et al tyrosine phosphorylation level of EGFR, which indicates its activation status, was downregulated in both virus-infected cells and stable clone cells (Figure 2d ). Furthermore, we observed a mild decrease of both total and phosphorylated stat3 (pY705) in U373/ephrinA5 cells (Figure 2c ). Ligand-bound EGFR can recruit and activate stat3 by phosphorylation, thus the decreased phosphorylation level of both stat3 (pY705) and EGFR itself suggested the impaired EGFR signaling. To test this hypothesis, we examined the activation of Ras-Raf-MEK-ERK (extracellular signal-regulated kinase) pathway upon epidermal growth factor (EGF) stimulation, which is a key pathway downstream of EGFR. As shown in Figure 3b , ERK phosphorylation triggered by EGF stimulation was obvious in both U373/v and U373/ephrinA5 cells at 10 min. Whereas the level of phospho-ERK was comparable between U373/v and U373/ephrinA5L cells, it was much lower in U373/ ephrinA5H cell at this time point. Furthermore, the level of ERK (pT202/pY204) declined more rapidly in both U373/ephrinA5 cells compared with U373/v cells during the treatment. At 120 min, phospho-ERK was quite weak in U373/ephrinA5 cells, whereas it was still readily detectable in control cell. Thus, the response to EGF stimulation was actually impaired in U373/ephrinA5 cells, consistent with the decreased EGFR level. The close correlation between the response to EGF stimulation and the expression level of EGFR has been strongly proved in EGFR-knockdown U373 cells (Supplementary Figure 1b and c).
EphrinA5-facilitated EGFR degradation by promoting c-Cbl binding and ubiquitylation
Ubiquitylation of EGFR and subsequent degradation is a well-known mechanism regulating its level. Thus, we examined the effect of ephrinA5 on EGFR stability. We used human embryonic kidney (HEK-293T) cells instead of U373 cells because of the relatively low level of EGFR and much lower transfection efficiency in the latter. When ectopically expressed in HEK-293T cells, ephrinA5 resulted in decreased level of EGFR, reminiscent of what we observed in either stable cell lines or clinical samples (Figure 4a ). Furthermore, the suppression of EGFR by ephrinA5 was in a dose-dependent manner ( Figure 4a ). Interestingly, one EGFR mutant (Y1045F) showed resistance to downregulation by ephrinA5 ( Figure 4a ). The 1045 tyrosine of EGFR provides a docking site for c-Cbl, which sorts the receptors for degradation by tagging them with ubiquitin (Oksvold et al., 2003) . We assumed that ephrinA5 might influence c-Cbl binding to EGFR. To test this hypothesis, EGFR was immunoprecipitated in the absence or presence of ephrinA5 in HEK-293T cells, and then the ubiquitylation and c-Cbl association was examined. As expected, ubiquitylation of EGFR was significantly enhanced when ephrinA5 was present ( Figure 4b ). Consistent with the enhanced ubiquitylation, more c-Cbl bound to EGFR when ephrinA5 was co-expressed ( Figure 4b ). This result strongly supported our hypothesis that ephrinA5 could promote the association of c-Cbl with EGFR, thus enhancing ubiquitylation and degradation of this receptor.
EphrinA5-Fc treatment-induced EGFR decrease and sustained EGF-mediated EGFR degradation
Bidirectional signaling in 'Eph/ephrin' system is responsible for a variety of biological events. The signaling pathway downstream of the transmembrane Eph RTKs is referred to as Eph forward signaling, whereas that downstream of ephrins is referred to as ephrin reverse signaling. We first investigated whether the forward signaling was involved in ephrinA5-mediated EGFR degradation. Several EphA receptors are expressed in U373 parental cells, such as EphA2 and EphA4, which decrease in U373/ephrinA5 cells (Supplementary Figure 1a) . We employed ephrinA5-Fc fusion protein to mimic forward signaling activation (Supplementary Figure 2a) . Treating U373 cells with ephrinA5-Fc resulted in decreased EGFR level (Figure 5a ). However, the extent of EGFR decrease induced by ephrinA5-Fc was milder than that in HEK-293T cells (Figure 5b ), possibly because of the relatively lower basal and phosphorylation level of To further investigate the effect of ephrinA5-Fc on ligand-activated EGFR, we treated U373 cells with a combination of EGF and either control or ephrinA5-Fc, and examined the degradation of EGFR by immunofluorescence. As shown in Figure 5c , there was no difference between the control-Fc and ephrinA5-Fc treatment at the beginning (1 min). Endocytic vesicles bearing EGFR signals were observed in differently treated cells. The green signals representing ephrinA5-Fc exhibited a typical membrane distribution, suggesting its ligation to the cognate receptors. However, at 30 min, no detectable EGFR signals appeared on the membrane of ephrinA5-Fc-treated cells, whereas membrane EGFR staining in control cells was visible despite being weak. Figure 5c also showed that by 30 min, ephrinA5-Fc aggregated around the nuclei, indicating its lysosomal degradation. The difference in membrane EGFR level extended to as long as 120 min. At this time point, both of the cells showed perinuclear EGFR signals, indicating degraded receptors. However, membrane EGFR recovered, at least partially, in control cells, whereas it remained undetectable in ephrinA5-Fctreated cells. This difference was further proved by the phase separation of membrane EGFR (120 min) (Figure 5d ). The above results suggested that the forward signaling activated by ephrinA5 could prolong EGF-induced EGFR degradation and prevent membrane EGFR recovery. Thus, the Eph forward signaling should contribute to the negative regulation of EGFR by ephrinA5.
EphA2-Fc treatment also reduced EGFR in either HEK-293T cells or U373/ephrinA5 cells Both EGFR and ephrinA5 were reported to reside in a specific microdomain on the membrane in which various downstream signals could be transduced. Although ephrinA5 is a glycosylphosphatidylinositol-linked membrane protein, it is also able to elicit intracellular signaling transduction, such as activation of Src family kinases (Davy et al., 1999) . We supposed that the ephrin reverse signaling also participated in the downregulation of EGFR, considering the presence of endogeneous EphA receptors for ephrinA5. Firstly, we examined the localization of EGFR and ephrinA5 in U373/ephrinA5 cells. As expected, the two molecules showed nearly identical colocalization on the membrane. proteins on U373 cells. U373 cells were plated on cover slides. Serum-starved cells were stimulated with a combination of EGF (50 ng/ ml) and Fc recombinant proteins (2 mg/ml). The samples were fixed at different time points and localization of EGFR and ephrinA5-Fc were examined by immunofluorescence (Green, ephrinA5-Fc; Red, EGFR). (d) In the treatment described in (c) membrane EGFR (120 min) was isolated by phase separation method using Triton X-114, and subjected to immunoprecitation analysis. IP, immunoprecipitation.
EphrinA5 suppresses tumorigenesis in glioma J-J Li et al
Owing to the rather low ephrinA5 expression level in all the available glioma cell lines (data not shown), we instead employed HEK-293T cells to examine the effect of ephrin reverse signaling on EGFR. HEK-293T cells co-overexpressing EGFR and ephrinA5 were treated with EphA2-Fc to activate the reverse signaling. As shown in Figure 6b , EphA2-Fc caused reduced level of EGFR compared with control Fc, and was associated with decreased ephrinA5 and increased Fyn (pY416) (Supplementary Figure 2b) , indicating the activation of ephrinA5 reverse signaling. We performed the same treatment on cells expressing EGFR alone to preclude the possibility that decreased level of EGFR was due to other endogenous ligands for EphA2 in HEK-293T cells other than ephrinA5. EGFR expression showed little change upon EphA2-Fc treatment in the absence of ephrinA5, proving that the suppressive effect on EGFR was mainly mediated through ephrinA5.
The same treatment was also conducted on U373/ ephrinA5 cells, using U373 parental cells as control, and similar results were observed (Figure 6c) . However, the change of EGFR was less dramatic than that in HEK-293T cells, possibly due to the relative lower expression level of both EGFR and ephrinA5 in U373/ ephrinA5 cells. These results suggested that the ephrin reverse signaling as well as the forward signaling participated in the downregulation of EGFR by ephrinA5.
Discussion
A majority of earlier studies focused on the role of ephrinA5 in developmental biology, especially the nervous system (Bolz et al., 2004; Otal et al., 2006) . Recently, the role of ephrinA5 in cancer has gained attention, and the expression pattern of ephrinA5 has been examined in several types of cancers, such as ovarian cancer (Herath et al., 2006) and osteosarcoma (Varelias et al., 2002) . In this study, we showed that ephrinA5 played as a suppressor in glioma through its negative regulation on EGFR, which is frequently aberrant in glioma.
Dysregulation of EGFR signaling contributes a large part to the development and malignant nature of highgrade gliomas (Halatsch et al., 2006) . Thus, regulation of this receptor has been largely investigated to find indications for clinical therapy. Ubiquitylation of EGFR and subsequent degradation controls the intensity of downstream signals after receptor activation. c-Cbl, a ubiquitin E3 ligase, is recruited to EGFR upon ligand stimulation, and then initiates the ubiquitylation of the activated receptor (Joazeiro et al., 1999; Levkowitz et al., 1999) . The ubiquitylated EGFR is internalized into early endosomes, from where it is either recycled to plasma membrane, or delivered to multivesicular bodies and late endosomes for degradation (Waterman and Yarden, 2001; Ravid et al., 2004) . In our study, we reported for the first time that ephrinA5 could enhance c-Cbl association with EGFR and subsequent ubiquitylation of the receptor, and thereby promote EGFR degradation. Owing to various mitogens contained in the cell culture medium, increased EGFR-associated c-Cbl and enhanced receptor degradation could be detected even without additional EGF stimulation. Owing to the rather low EGFR level, it was impossible to perform the immunoprecipitation assay in U373/ephrinA5 cells. However, this mechanism should contribute to decreased EGFR level in U373/ephrinA5 cells.
EphrinA5 is a glycosylphosphatidylinositol-linked protein tethered to the plasma membrane. This raised the question, how it can influence the interactions between c-Cbl and EGFR in the cytoplasmic region to negatively regulate EGFR. The forward and reverse bidirectional signal transduction distinguishes Eph/ ephrin family from other RTK families. In this study, ephrinA5-Fc and EphA2-Fc treatments were used to mimic the activation of the forward and reverse signals, respectively. Several EphA receptors were expressed in U373 cells, and could be activated after ephrinA5-Fc stimulation, accompanied with elicitation of the forward signal (Supplementary Figure 1a, 2a and c) . c-Cbl has been reported to participate in EphA receptor degradation induced by ligand stimulation (Walker-Daniels et al., 2002; Wang et al., 2002; Sharfe et al., 2003) . Larsen et al., 2007 showed that other than transcriptional target of EGFR, EphA2 colocalized with activated EGFR. Thus, recruitment of c-Cbl by activated EphA receptor upon ligand binding potentially facilitates its access to EGFR, and promotes subsequent ubiquitylation of the receptor, which could interpret the potential role of Eph forward signaling. Glycosylphosphatidylinositol-anchored ephrinA5 can induce compartmentalized signaling within a membrane microdomain when bound to its cognate Eph receptor. This signaling seemed to require the activity of the Fyn protein tyrosine kinase (Davy et al., 1999) . We showed that ephrinA5 colocalized with EGFR in certain regions on the plasma membrane. As phosphorylation by Fyn has been reported to regulate the E3 ligase activity of c-Cbl (Grossmann et al., 2004; Li et al., 2007) , we hypothesize that the ephrinA5 reverse signaling triggered by EphA2-Fc would activate Fyn, which could phosphorylate c-Cbl, and facilitate c-Cbl-mediated EGFR degradation.
In transiently transfected HEK-293T cells, parental U373 cells and U373/ephrinA5 cells, EGFR was attenuated in response to ephrinA5-Fc or EphA2-Fc treatment. However, the reduction of EGFR was less significant in U373 or U373/ephrinA5 cells when compared with HEK-293T cells. This might be due to the much higher expression level of extrogenous EGFR and ephrinA5 in transfected HEK-293T cells, which possibly enhanced the intensity of signals, and led to more pronounced phenotype. As shown in Supplementary Figure 2c , in U373/ephrinA5 cells, despite reduced membrane expression of EphA2, its localization exhibited obvious overlap with ephrinA5 in the same cell. Their colocalization indicated potential cooperation on the suppression of EGFR expression. As mentioned above, it is possible that activation of Src family kinases through ephrinA5 reverse signaling, combined with the stimulation of EphA2 forward signaling, can facilitate the activation and recruitment of c-Cbl to EGFR synergistically, and thus enhance the subsequent EGFR degradation. Therefore, the negative regulation of EGFR by ephrinA5 is an integrated event combining multiplex signalings and effects.
In addition to protein stability, EGFR can also be regulated at the transcriptional level. It was reported that expression of the human EGFR gene could be regulated by ligand-activated thyroid hormone receptor (Xu et al., 1993) and estrogen . We also examined the mRNA level of EGFR in transfected U373 cells, and found it decreased by more than 50% in the U373/ephrinA5 cells compared with U373/v cells (Supplementary Figure 3a) . EGFR promoter reporter assay showed that ephrinA5 could suppress the promoter activity in a dose-dependent manner (Supplementary Figure 3b) . However, this suppression was modest, which could not fully interpret the dramatic decrease in the level of EGFR in stable cell lines. Taken together, ephrinA5 can negatively regulate EGFR at multilevels.
Oncogenic dysregulation of RTK signals usually involves the inactivation of negatively regulating tumor suppressor gene products, which is the case of ephrinA5 in our study. Our results suggest that glioma cells possibly silence ephrinA5 expression to avoid its suppressive effect on EGFR. The downregulation of EGFR by ephrinA5 also provides new insights into the intricate interaction between the signaling pathways of ErbB and Eph RTK families. Aberrant expression and activation of EGFR represents one of the major molecular alterations resulting in malignancy in glioma. Although a variety of agents targeting EGFR have been developed, their antitumor effects are often not as optimal as predicted from preclinical studies. Their modest activity is possibly due to the complex modulation of strongly enhanced EGFR signaling pathway in glioma. Further understanding of the negative regulation on EGFR by ephrinA5 will expand our knowledge of the molecular pathogenesis of glioma. Moreover, our work indicates that therapeutic intervention using existing anti-EGFR agents combined with ephrinA5-related signal activation will potentially improve the drug efficacy.
Materials and methods
Tissue samples and cell culture Forty-six brain tumor samples, all of which are glioblastoma multiforme, and five normal brain samples were obtained from Cedars-Sinai Medical Center, UCLA School of Medicine at the time of surgery after the pathology specimens had been obtained. Part of each tissue sample was quick frozen in liquid nitrogen and stored at À70 1C until they were processed, whereas the remaining tissue was used for primary cell culture. Our work was approved by the Institutional Review Board of the Institute for Nutritional Sciences, Chinese Academy of Sciences. HEK-293T cells, HeLa cells, U343 and U373 glioma cells, were maintained in Dulbecco's modified Eagle's medium (GIBCO, GrandIsland, NY, USA) supplemented with 10% fetal bovine serum (Hyclone, Logan, UT, USA) at 37 1C in a humidified atmosphere containing 5% CO 2 .
Antibodies and reagents
Anti-ephrinA5 antibody and recombinant human EGF were purchased from R&D Systems (Minneapolis, MN, USA) . Anti-EGFR, anti-Stat3, anti-b-actin, anti-a-tubulin and antiUbiquitin antibodies were obtained from Santa Cruz Biotechnology Inc. (Santa Cruz, CA, USA). Anti-EphA4 and PY20 antibodies were from BD Transduction Laboratories (San Diego, CA, USA). Anti-Fyn and anti-EphA2 antibodies were from Chemicon (Temecula, CA, USA) and Upstate (Lake Placid, NY, USA), respectively. Anti-ERK1/2, anti-phospho-ERK1/2 (pT202/pY204), anti-phospho-Stat3 (pY705), antiphospho-Src family (Tyr416) and horseradish peroxidaseconjugated secondary antibodies were purchased from Cell Signaling Technology Inc. (Danvers, MA, USA). The secondary antibodies for immunofluorescence were from Molecular Probe Inc. (Eugene, OR, USA).
RNA preparation and Real-Time PCR Preparation and construction of RNA and cDNA preparation were done as described earlier (Xie et al., 2004) . The primer pairs used for real-time PCR are as follows: ephrinA5: F:
0 . Amplification reactions were performed as described earlier (Deng et al., 2007) .
Plasmids construction and cell transfection
To generate the ephrinA5 expression vector, the open reading frame of human ephrinA5 cDNA was cloned into the eukaryotic expression vector pcDNA3.1 (Invitrogen, Carlsbad, CA, USA) and was fused to a C-terminal myc tag. The expression construct and empty pcDNA3.1 vector were transfected into U373 cells, respectively, using Lipofectamine 2000 Reagent (Invitrogen). The transfected cells were selected in the presence of 800 mg/ml G418 and resistant clones were further confirmed by western blot analysis. A modified lentivirus-based FG12 vector with a cytomegalovirus promoter (Sun et al., 2008) was also used to overexpress human ephrinA5. HEK-293T cells were transfected using the calcium phosphate precipitation method, and HeLa cells were transfected using FuGENE6 Transfection Reagent (Roche Applied Sciences, Penzberg, Germany). EphrinA5-Fc fusion protein was generated as described earlier (Munthe et al., 2000) , and the primer pair for the construct was: F: 5 0 -CATAAGCTTC CACCATGTTGCACGTGGAGATGTT-3 0 , R: 5 0 -ATCGGAT CCTGACTCATGTACGGTGTC-3 0 . To knockdown the endogenous EGFR, three small interfering RNA sequences against different sites of hEGFR mRNA were designed using the online software 'siRNA Target Finder' (Ambion Inc., Austin, TX, USA): (1) GGCACGAGTAACAAGCTCA; (2) GAGAAAGAATAC CATGCAG; (3) GTGCTGGATGATAGACGCA. Oligonucleotide with a scrambled sequence was used as a negative control. RNA interference constructs were cloned and produced as described earlier (Qin et al., 2003) .
The following constructs were kindly provided:
EGFR promoter reporter plasmid (pER-Luc) from Dr Alfred C. Johnson (Liu et al., 2000) ; Expression constructs for hEGFR and hEGFR (Y1045F) mutant were from Dr Yosef Yarden (Levkowitz et al., 1999) ; pcDNA3.1-HA-Ubiquitin from Dr De Camilli P; CD19-Fc and EphA2-Fc expression vectors from Dr Hans-Christian Aasheim (Finne et al., 2004) .
Luciferase reporter assay HeLa cells were plated at subconfluent density in 24-well dishes and cotransfected with a total of 0.5 mg plasmids, including 0.1 mg reporter plasmid, different amounts of empty or expression vector and 0.05 mg Renilla luciferase pRL-TK plasmid. Cell lysates were prepared 24 h after transfection, and reporter activity was measured using the Dual-Luciferase Reporter Assay System (Promega, Madison, WI, USA). Transfections were performed in triplicate, and repeated thrice to ensure reproducibility.
Immunofluorescence microscopy Cells (U373, U373/v or U373/ephrinA5) were digested with trypsin and plated on cover slides. On the next day, the cells were washed thrice with phosphate buffered saline (PBS) at room temperature, and fixed in 4% formaldehyde on ice for 30 min. Cells were blocked with 2% bovine serum albumin at room temperature for 1 h. Primary antibody incubations were performed overnight at 4 1C (ephrinA5, 1:100; EGFR, 1:100; EphA2, 1:200). After extensive washing with PBS, secondary antibody (Alexa Fluor 488-conjugated donkey anti-rabbit, mouse, goat IgG and Alexa Fluor 555-conjugated goat antimouse, rabbit and donkey anti-goat IgG, 1:1000) incubations were performed at room temperature for 1 h. Samples were washed again with PBS and then mounted in Mowiol 4-88 (Sigma-Aldrich Inc., St Louis, MO, USA). Fluorescence was monitored by inverted confocal laser microscopy (Carl Zeiss, NY, USA).
Protein extraction with Triton X-114 U373 cells treated with Fc fragments were lysed with Triton X-114 extraction buffer (10 mM Tris (pH 7.4), 150 mM NaCl, 1% Triton X-114). The proteins were subjected to phase separation as described earlier (Bordier, 1981) . Briefly after removal of the particulate matter by centrifugation, the sample was layered over a 6% (w/v) sucrose cushion, warmed to 30 1C to separate the phases and centrifuged at 300 g at room temperature. The detergent phase (an oily droplet at the bottom of the tube) was diluted and analysed by Immunoprecipitation.
Immunohistochemistry
Glioblastoma multiforme and normal brain tissues were fixed in formalin, embedded in paraffin, and 10mm-thick consecutive sections were cut and mounted on glass slides. The sections were fixed in ice-cold acetone for 30 min, washed thrice in 0.01 mol/l PBS (8 mmol/l Na 2 HPO 4 , 2 mmol/l NaH 2 PO 4 and 150 mmol/l NaCl) for 5 min each, blocked for 1 h in 0.01 mol/l PBS supplemented with 0.3% Triton X-100 and 5% normal goat serum, followed by addition of ephrinA5 (1:100) antibody at 4 1C overnight. After brief washes in 0.01 mol/l PBS, sections were exposed for 2 h to 0.01 mol/l PBS containing horseradish peroxidase-conjugated rabbit anti-goat IgG (1:500), followed by development with 0.003% H 2 O 2 and 0.03% 3,3 0 -diaminobenzidine in 0.05 mol/l Tris-HCl (pH 7.6). Immunohistochemistry for each sample was performed at least three separate times, and all sections were counterstained with hematoxylin. Negative controls consisted of substitution of the primary antibody with normal goat serum at the same dilution.
Western blot analysis
Cultured cells were washed twice with PBS and lysed in radioimmunoprecipitation assay buffer for 15 min on ice. Glioma tissues were also extracted with radioimmunoprecipi-tation assay buffer. Cell lysates were clarified by centrifugation at 10 000 g for 15 min, and protein concentration was determined by the Bradford Reagent (Rio-Rad Laboratories, Hercules, CA, USA). Lysates were separated on either 10% or 8% sodium dodecyl sulfate polyacrylamide gel electrophoresis, proteins were then transferred to Immobilon membrane (Millipore, Bedford, MA, USA) and immunoblotted with indicated antibodies. All immunoblots were visualized by enhanced chemiluminescene (Pierce, Rockford, IL, USA). The band intensity was quantified by arithmetic analysis using the software Scion Image beta 4.03. The ratios of EGFR/tubulin expression between different lanes were marked in the form of relative values under the blots. Statistical analysis was carried out with Pearson correlation test.
Immunoprecipitation Cells were washed with ice-cold PBS and lysed in Tris-buffered saline (pH 7.4), containing 50 mM Tris, 150 mM NaCl, 1% NP-40, 1 mM EDTA, 1 mM Na 3 VO 4 , 10mM NaF, 2.5 mg/ml aprotinin and leupeptin, 1 mM b-glycerophosphate and AEBSF (4-(2-aminoethyl) benzenesulfonyl fluoride hydrochloride), and 10 mM iodoacetate. Lysates were incubated on ice for 15 min before cellular debris and nuclei were removed by centrifugation at 5000 g for 5 min. Cell lysates were incubated with anti-EGFR antibody overnight at 4 1C. Protein A-Sepharose (Amersham Biosciences, Piscataway, NJ, USA) beads in a 50:50 mixture in 50 mM Tris buffer, pH 7.0, were added, and further incubated for another 4 h at 4 1C. The immunoprecipitates were washed thrice in Tris-buffered saline and boiled for 5 min in 100 ml Laemmli buffer containing 0.02% blue bromophenol and 2% bmercaptoethanol.
Soft agar assay
For clonogenic assay, cells were plated into 24-well flatbottomed dishes using a two-layer soft agar system with 1.0 Â 10 3 cells per well in a volume of 400 ml per well. After 20 days of incubation, the colonies were counted and measured. All of the experiments were done at least thrice using triplicate plates per experimental point.
Tumorigenicity assay
Six 8-week-old nude mice were separated into two groups. The experimental group received 1.0 Â 10 6 U373/ephrinA5 cells subcutaneously injected on opposite flanks; the control group received subcutaneously lateral blank injection of 1.0 Â 10 6 U373/v cells. Tumors were harvested 4 weeks after injection and individually measured. Tumor volumes (mm 3 ) were calculated using the standard formula: length Â width Â height Â 0.5326. Statistical analysis was performed using the Student's t test.
